|
시장보고서
상품코드
2130890
리피테그라스트 API 시장 규모, 점유율 및 성장 분석 : 등급별, 제조 프로세스 분석, 순도별, 용도별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Lifitegrast API Market Size, Share, and Growth Analysis, By Grade, By Manufacturing Process, By Purity, By Application, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 리피테그라스트 API 시장 규모는 2024년에 1억 1,800만 달러로 평가되며, 2025년 1억 2,791만 달러에서 2033년까지 2억 4,387만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 8.4%로 성장할 것으로 전망되고 있습니다.
전 세계 리피테그라스트 API 시장은 성인 인구의 상당 부분에 영향을 미치는 안구건조증 치료용 점안액에 사용되는 유효 성분을 대상으로 합니다. 리피테그라스트가 LFA-1/ICAM-1 경로를 억제하는 능력은 안구 염증을 완화하는 새로운 방법을 제공하며, 이로 인해 처방량 증가와 제조사의 생산 확대가 이어지고 있습니다. 대형 제약사 및 제네릭 의약품 제조사를 포함한 초기 진입 기업은 위탁 생산을 활용하여 왔지만, 신흥 시장에서는 현지 합성 역량이 확립되어 있습니다. 이러한 변화로 인해 리피테그라스트는 틈새 제품에서 치료 솔루션의 주류 제품으로 전환되었습니다. 고령화와 스크린 타임의 영향으로 인한 만성 안과 질환 유병률 상승 등의 요인이 수요를 견인하는 한편, AI의 발전으로 제형 및 환자 맞춤형 치료가 최적화되어 시장의 접근성과 효율성이 향상되고 있습니다.
전 세계 리피테그라스트 API 시장의 성장 요인
전 세계 리피테그라스트 원료의약품(API) 시장의 주요 성장 동인 중 하나는 특히 고령층이나 화면 시청 시간 및 대기 오염과 같은 환경적 스트레스 요인에 노출된 사람들을 중심으로 안구 건조증 유병률이 증가하고 있다는 점입니다. 증례의 급증으로 인해 이 질환에 수반되는 증상을 치료하기 위한 새로운 작용 기전을 가진 리피테그라스트와 같은 효과적인 치료법에 대한 수요가 높아지고 있습니다. 또한 눈 건강에 대한 의식의 향상와 안과 연구의 발전도 시장을 지원하고 있으며, 제약사들이 안과 의료 분야의 미충족 의료 수요에 대응하는 혁신적인 치료법의 개발 및 상용화에 투자하도록 촉진하고 있습니다.
전 세계 리피테그라스트 API(원료의약품) 시장의 제약 요인
전 세계 리피테그라스트 API 시장의 주요 억제요인 중 하나는 의약품 제조 및 승인을 규제하는 엄격한 규제 환경입니다. 엄격한 안전성 및 유효성 기준을 준수해야 하는 것은 생산 비용 증가와 제품 출시까지의 기간 연장으로 이어질 수 있습니다. 또한 규제 변화 속에서 필요한 인증을 획득하고 품질 보증을 유지하는 데 따르는 복잡성은 제조업체의 성장을 저해하는 요인이 될 수 있습니다. 이에 더해, 대체요법으로부터의 잠재적 경쟁과 끊임없는 혁신에 대한 압박이 맞물리면서 리피테그라스트 개발에 대한 관심과 자원이 분산되어 시장 확대와 접근성 향상을 제한할 가능성이 있습니다.
전 세계 리피테그라스트 API 시장 동향
전 세계 리피테그라스트 API 시장에서는 정밀 제조 기술의 발전에 힘입어 뚜렷한 동향이 나타나고 있습니다. 제약사들은 리피테그라스트 API 생산의 일관성과 품질을 향상시키고, 배치 간 편차를 효과적으로 최소화하기 위해 이러한 혁신을 우선시하고 있습니다. 이러한 전략적 집중은 생산 공정의 규모 확대를 가속화할 뿐만 아니라, 의료 전문가들 사이에서 제품 품질에 대한 평가를 높이고, 지속가능한 제조 방식으로의 업계 전반적 흐름과도 부합합니다. 그 결과, 이러한 역량을 도입한 제조사들은 경쟁 우위를 확립하고, 생명공학 분야의 제휴를 유치하는 동시에 신뢰할 수 있는 안구건조증 치료제에 대한 증가하는 수요에 부응하고 있습니다. 이러한 추세는 시장 성장을 촉진하고, 전 세계 안과 치료 분야 전반에 걸쳐 브랜드에 대한 신뢰를 강화하고 있습니다.
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 리피테그라스트 API 시장 규모 : 등급별
세계의 리피테그라스트 API 시장 규모 : 제조 프로세스별
세계의 리피테그라스트 API 시장 규모 : 순도별
세계의 리피테그라스트 API 시장 규모 : 용도별
세계의 리피테그라스트 API 시장 규모 : 최종사용자별
세계의 리피테그라스트 API 시장 규모 : 유통 채널별
세계의 리피테그라스트 API 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSAGlobal Lifitegrast Api Market size was valued at USD 118.0 Million in 2024 and is poised to grow from USD 127.91 Million in 2025 to USD 243.87 Million by 2033, growing at a CAGR of 8.4% during the forecast period (2026-2033).
The global Lifitegrast API market is targeting the active ingredient used in eye-drop treatments for dry-eye disease, impacting a significant percentage of the adult population. Lifitegrast's ability to inhibit the LFA-1/ICAM-1 pathway offers a novel method to alleviate ocular inflammation, leading to increased prescriptions and expanded production from manufacturers. Early market entrants, including pharmaceutical giants and generic providers, have leveraged contract manufacturing while emerging markets have established local synthesis capabilities. This evolution has transitioned Lifitegrast from a niche product to a mainstream offering in therapeutic solutions. Factors such as the rising incidence of chronic ocular conditions, influenced by aging populations and screen time, are propelling demand, while advancements in AI are optimizing formulations and patient-specific treatments, thereby boosting market accessibility and efficiency.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lifitegrast Api market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Lifitegrast Api Market Segments Analysis
Global lifitegrast api market is segmented by grade, manufacturing process, purity, application, end user, distribution channel and region. Based on grade, the market is segmented into Pharmaceutical Grade and Research Grade. Based on manufacturing process, the market is segmented into Synthetic and Biotechnological. Based on purity, the market is segmented into Below 98%, 98%-99% and Above 99%. Based on application, the market is segmented into Commercial Manufacturing and Clinical Research. Based on end user, the market is segmented into Pharmaceutical Companies, Contract Manufacturing Organizations and Research Institutes. Based on distribution channel, the market is segmented into Direct Sales and Distributors. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Lifitegrast Api Market
One of the key market drivers for the global Lifitegrast API market is the increasing prevalence of dry eye disease, particularly among the aging population and those exposed to environmental stressors like screen time and pollution. This surge in cases heightens the demand for effective therapeutic options, such as Lifitegrast, which offers a novel mechanism for treating symptoms associated with this condition. Additionally, the growing emphasis on eye health awareness and advancements in ophthalmological research further bolster the market, encouraging pharmaceutical companies to invest in the development and commercialization of innovative treatments that address unmet medical needs in eye care.
Restraints in the Global Lifitegrast Api Market
One key market restraint for the global Lifitegrast API market is the stringent regulatory environment governing pharmaceutical manufacturing and drug approvals. Compliance with rigorous safety and efficacy standards can lead to increased production costs and extended timelines for bringing products to market. Additionally, the complexities associated with obtaining necessary certifications and maintaining quality assurance amidst evolving regulations can hinder the growth of manufacturers. This is further compounded by potential competition from alternative therapies and the constant pressure to innovate, which may divert focus and resources away from Lifitegrast development efforts, limiting its market expansion and accessibility.
Market Trends of the Global Lifitegrast Api Market
The Global Lifitegrast API market is witnessing a significant trend driven by advancements in precision manufacturing technologies. Pharmaceutical companies are prioritizing these innovations to enhance the consistency and quality of lifitegrast API production, effectively minimizing batch variability. This strategic focus not only accelerates scaling processes but also elevates product quality perceptions among healthcare professionals, aligning with the industry's broader movement towards continuous processing methods. Consequently, manufacturers adopting such capabilities are positioning themselves competitively, attracting partnerships within the biotech sector, and meeting the rising demand for dependable dry-eye treatments. This dynamic fosters market growth and strengthens brand trust across the global ophthalmic therapeutic landscape.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Lifitegrast API Market Size by Grade & CAGR (2026-2033)
- Market Overview
- Pharmaceutical Grade
- Research Grade
Global Lifitegrast API Market Size by Manufacturing Process & CAGR (2026-2033)
- Market Overview
- Synthetic
- Biotechnological
Global Lifitegrast API Market Size by Purity & CAGR (2026-2033)
- Market Overview
- Below 98%
- 98%-99%
- Above 99%
Global Lifitegrast API Market Size by Application & CAGR (2026-2033)
- Market Overview
- Commercial Manufacturing
- Clinical Research
Global Lifitegrast API Market Size by End User & CAGR (2026-2033)
- Market Overview
- Pharmaceutical Companies
- Contract Manufacturing Organizations
- Research Institutes
Global Lifitegrast API Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Direct Sales
- Distributors
Global Lifitegrast API Market Size & CAGR (2026-2033)
- North America (Grade, Manufacturing Process, Purity, Application, End User, Distribution Channel)
- US
- Canada
- Europe (Grade, Manufacturing Process, Purity, Application, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Grade, Manufacturing Process, Purity, Application, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Grade, Manufacturing Process, Purity, Application, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Grade, Manufacturing Process, Purity, Application, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MSN Laboratories Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hetero Labs Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shilpa Medicare Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Divi's Laboratories Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lee Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sai Life Sciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Laurus Labs Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aarti Pharmalabs Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Metrochem API Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurore Life Sciences Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shandong Xinhua Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- TAPI
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
